Brief: Rhythm Pharmaceuticals Announces Multiple New Data Presentations From Mc4r Agonists
15/06/2026 21:02
BRIEF-Rhythm Pharmaceuticals Announces Multiple New Data Presentations From Mc4r Agonists June 15 (Reuters) - Rhythm Pharmaceuticals Inc RYTM.O:
RHYTHM PHARMACEUTICALS ANNOUNCES MULTIPLE NEW DATA PRESENTATIONS FROM MC4R AGONISTS IN ACQUIRED HYPOTHALAMIC OBESITY (HO), BARDET-BIEDL SYNDROME (BBS) AND PRADER-WILLI SYNDROME (PWS) AT ENDO 2026
Source text: ID:nGNX6ylYsQ
Further company coverage: RYTM.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Rhythm Pharmaceuticals
See all newsBrief: Rhythm Pharmaceuticals Announces Appointment Of Manher (Aj) Joshi As Chief Medical Officer
Rhythm's drug shows promise for brain tumor-related weight condition in small study (updated)
Rhythm Pharmaceuticals Inc reports results for the quarter ended June 30 - Earnings Summary
Rhythm Pharma's obesity drug shows promise for brain tumor-related weight condition
Rhythm Pharmaceuticals Q2 net loss narrows on US launch demand